日本皮膚科学会雑誌第120巻第5号

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "日本皮膚科学会雑誌第120巻第5号"

Transcription

1

2 6 A B 1 2 α β 3

3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3 サイトプリン ペンタデカン CQ3.4 セファランチン CQ3.5 ケトコナゾール CQ4 男性型脱毛症にフィナステリド内服は有用か? (CQ4.1) 男性の男性型脱毛症 (CQ4.2) 女性の男性型脱毛症 CQ5 男性型脱毛症に植毛術は有用か? (CQ5.1) 自毛植毛術 (CQ5.2) 人工毛植毛術 推奨度 A A C1 C1 C1 C1 C2 C1 A D B D Clinical Questions JAmAcad Dermatol Dermatol Clin J Am Acad Dermatol Disorders of hair growth : diagnosis and treatment J Am Acad Dermatol Hair Research

4 図 1 Am JAnatomy Nat Genet J Invest Dermatol Symp Proc CQ1

5 J Am Acad Dermatol J Am Acad Dermatol J Am Acad Dermatol J Am Acad Dermatol JAmAcad Dermatol J Dermatol Eur J Dermatol Int J Dermatol Arch Dermatol JCutan Med Surg CQ2 γ γ

6 CQ3 CQ3.1 t- µ CQ3.2 µ µ µ J Dermatol

7 CQ3.3 CQ3.4 CQ3.5 µ

8 J Dermatol Sci Dermatology CQ4 α J Am Acad Dermatol

9 J Am Acad Dermatol JAmAcadDermatol α J Am Acad Dermatol Br J Dermatol Eur J Dermatol Eur J Dermatol Eur J Dermatol J Am Acad Dermatol Eur J Dermatol J Am Acad Dermatol Lancet Oncol J Am Acad Dermatol CQ5

10 Hair Transplantation J Am Acad Dermatol

11 terminal hair placebo (93) terminal hair placebo- vellus hair 24 base line 8.5 cm, cm, cm

12 2 30 ( 12 ) 10 38% % non vellus hair (intermediate hair terminal hair ) placebo (4) total hair placebo- vellus hair 12 placebo-3%minoxidil (83%)

13 placebo placebo-

14 48 nonvellus hair placebo 3.9 5%minoxidil 5%minoxidil 5%minoxidil placebo

15 96 placebo

16 Nonvellus hair count: 5%minoxidil 26.4, 1% 21.2 p=0.02 5% Terminal hair count: 5%minoxidil 16.1, 1% 12.2 p= % total hair count: 5%minoxidil 22.3, 1% 17.2 p= %

17 minoxidil 56.3 plasebo 57.2 minoxidil Grade I 56.9% Grade II 43.1% plasebo Grade I 61.8% Grade II 38.2% minoxidil 6.86 plasebo 7.03 minoxidil /cm2 plasebo /cm2 6 non vellus hair 8.18 (placebo 2.03), vellus hair 7.00 (placebo 0.83), total hair (placebo 2.85) placebo 29.

18 minoxidil 33.1 placebo 34.2 minoxidil Grade I 52 Grade II 48 placebo Grade I 47 Grade II 53 minoxidil 8.0 placebo non vellus hair 33 placebo 19 44

19 minoxidil 33.6 placebo 34.4 minoxidil Grade I 48 Grade II 52 placebo Grade I 53 Grade II 47 minoxidil 9.5 plasebo non vellus hair 23 placebo 11 minimal 63

20 2%minoxidil % % % % % placebo % % % % % 12 excellent : 20.7%, 27.2% good: 43.4% 37.8% 447 (4.0%) placebo 547 (4.9%) 0.07% placebo 22 (0.20%) placebo 59 minoxidil

21

22 10 1-3

23 5

24 20%, 60.0%

25 2ml

26 t-

27 t-

28

29

30 3 (7%) CTP(47%)

31

32 5% 1% 4

33

34

35

36 RCT 3-alphadiol-glucuronide DHT 13.0%, 0.01, 0.05, 0.2, 1, 5 mg / 14.9%, 61.6%, 56.5%, 64.1%, 69.4%. 0.05, 0.2, 1, 5 mg /. DHT 0.01 /, 0.05, 0.2, 1, 5 mg / 49.5%, 68.6%, 71.4%, 72.2%. 3%, 1 mg 2.7%, 4.5%, 0.01 mg 2.7%, 0.05 mg 2.9%, 0.2 mg 8.3%, 1mg 0%, 5mg 2.6% II

37 α RCT II

38 RCT1 + 1 II

39 α RCT II

40 α RCT II

41 α

42 α

43 α

44 α RCT II

45 RCT II

46 RCT III

47 6 3 α RCT II

48 RCT II

研修コーナー

研修コーナー l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l

More information

日本皮膚科学会雑誌第122巻第7号

日本皮膚科学会雑誌第122巻第7号 Br J Dermatol NEnglJ Med 尋常性白斑診療ガイドライン 図 1 先天性白斑 白皮症の病型分類 図 2 後天性白斑 白皮症の病型分類 の尋常性白斑患者で家系内発症がみられることより 3 5 れらの合併が染色体 17p13 における一塩基多型に起 非分節 因し その候補遺伝子の一つが自然免疫に重要とされ 型に含まれる汎発型には甲状腺に対する抗サイログロ る NALP1 遺伝子であると報告している6

More information

第86回日本感染症学会総会学術集会後抄録(I)

第86回日本感染症学会総会学術集会後抄録(I) κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β

More information

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35

More information

日本皮膚科学会雑誌第121巻第12号

日本皮膚科学会雑誌第121巻第12号 Geriatrics Akt Dermato Eur J Vasc Endovasc Surg Ann R Coll Surg Engl Br J Surg Cochrane Database Syst Rev Cochrane Database Syst Rev Cochrane Database Syst Rev Cochrane Database Syst Rev Int wound J Eur

More information

日本皮膚科学会雑誌第121巻第11号

日本皮膚科学会雑誌第121巻第11号 β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis

More information

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

1 (1) (2)

1 (1) (2) 1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)

More information

- 2 -

- 2 - - 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -

More information

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1 1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4

More information

日本皮膚科学会雑誌第121巻第14号

日本皮膚科学会雑誌第121巻第14号 World J Surg Burns Burns JTrauma Lancet Lancet Surg Gynecol Obste J Burn Care Rehabil BMJ Pediatr Emerg Care The Treatment of Burns Burns, A Team Approach Surg Gynecol Obstet NEnglJMed J Burn Care Rehabil

More information

日本皮膚科学会雑誌第122巻第2号

日本皮膚科学会雑誌第122巻第2号 J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot

More information

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 81

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 81 9 CQ 1 80 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 81 CQ 2 82 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 83 84 CQ 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 85 CQ 4

More information

medicaljournal8.pdf

medicaljournal8.pdf Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry J Neurol Neurosurg Psychiatry Lancet

More information

cm H.11.3 P.13 2 3-106-

cm H.11.3 P.13 2 3-106- H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3

More information

日本皮膚科学会雑誌第119巻第5号

日本皮膚科学会雑誌第119巻第5号 I II 1 dermatophytosis tinea 1 2 3 tinea pedis Trichophyton rubrum 4 tinea manus 5 tinea unguium 2 candidiasis, candidosis 3 malassezia infection 4 sporotrichosis Sporothrix schenckii 5 dematiaceous fungal

More information

Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J

More information

表1.eps

表1.eps Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

More information

Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,

More information

日本皮膚科学会雑誌第120巻第8号

日本皮膚科学会雑誌第120巻第8号 1 2 3 4 5 6 付表 1 エビデンスのレベルと推奨度の決定基準 ( 皮膚悪性腫瘍グループ ) A. エビデンスのレベル分類 I I I IV V V I システマティック レビュー / メタアナリシス 1つ以上のランダム化比較試験による非ランダム化比較試験による分析疫学的研究 ( コホート研究や症例対照研究による ) 記述研究 ( 症例報告や症例集積研究による ) 専門委員会や専門家個人の意見

More information

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2) (1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46

More information

VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)

More information

nsg04-28/ky208684356100043077

nsg04-28/ky208684356100043077 δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

1. (1) 1/

1. (1) 1/ 2005 11 30 2006 03 31 1-1-2 [ ] 7-12 SMBC 4 1 27 1 18 1. (1) 1/5 1 2 32 1/5 1 2006 3 11 200 2006 1 1/5 20 20 30 CM 10 TVCM15 BB 2006 3 31 26 3 5 2 1 4 3 2 3 (2) (1) 2. (1) 1 2006/03/31 1,680,877,606 1

More information

i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii

More information

CRPNo30表紙.ai

CRPNo30表紙.ai No.30 2012/6 20126 Clinical Research Professionals No.30 17 18 Clinical Research Professionals No.30 2012 6 20126 Clinical Research Professionals No.30 19 20 Clinical Research Professionals No.30 2012

More information

2007050781......_.L.O...z.W

2007050781......_.L.O...z.W a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab

More information

1 10 1113 14 1516 1719 20 21 22 2324 25 2627 i 2829 30 31 32 33 3437 38 3941 42 4344 4547 48 4950 5152 53 5455 ii 56 5758 59 6061 iii 1 2 3 4 5 6 7 8 9 10 PFI 30 20 10 PFI 11 12 13 14 15 10 11 16 (1) 17

More information

untitled

untitled i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)

More information

23 15961615 1659 1657 14 1701 1711 1715 11 15 22 15 35 18 22 35 23 17 17 106 1.25 21 27 12 17 420,845 23 32 58.7 32 17 11.4 71.3 17.3 32 13.3 66.4 20.3 17 10,657 k 23 20 12 17 23 17 490,708 420,845 23

More information

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58

More information

I

I I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

More information

EV200R I II III 1 2 3 4 5 6 7 8 9 10 1 2 3 11 4 5 12 6 13 1 2 14 3 4 15 5 16 1 2 17 3 18 4 5 19 6 20 21 22 123 456 123 456 23 1 2 24 3 4 25 5 3 26 4 5 6 27 7 8 9 28 29 30 31 32 1 2 33 3 4 34 1 35 2 1

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30

More information

... 6

... 6 ... 6 1) 2) No. 01 02 03 04 05 06 07 08 09 10 11 12 No. 1 2 2 3 3cm 4

More information